Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 4 Interventional

Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors

ClinicalTrials.gov ID: NCT00944372

Public ClinicalTrials.gov record NCT00944372. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 7:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-Label, Multi-Center, Phase 4 Study to Evaluate the Effect of Age (Geriatric) and Renal Function on the Safety, Efficacy (Sensitivity, Specificity) and Pharmacokinetics of OctreoScan in Patients Referred for Scintigraphy of All Solid Tumors With a High Suspicion of Containing Somatostatin Receptor Positive Tissue

Study identification

NCT ID
NCT00944372
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 4
Lead sponsor
Mallinckrodt
Industry
Enrollment
150 participants

Conditions and interventions

Conditions

Interventions

  • Indium In-111 pentetreotide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2003
Primary completion
Jul 31, 2005
Completion
Jul 31, 2005
Last update posted
Sep 8, 2016

2003 – 2005

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
University of Miami, Jackson Memorial Hospital Miami Florida 33136
University of Iowa Medical Center Iowa City Iowa 52242
Louisiana State University, Division of Hem/Onc New Orleans Louisiana 70112
Hospital of University of Pennsylvania, Division of Nuclear Medicine Philadelphia Pennsylvania 19104

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00944372, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 8, 2016 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00944372 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →